spacer
home > pmps > autumn 2017 > supervising substances
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Supervising Substances

Since its conception in 2006, the Registration, Evaluation, Authorisation and restriction of CHemicals (REACH) regulation has had a significant impact on the chemical industry in the EU. The primary purpose of this legislation is to gain more knowledge about chemical substances so that companies can better protect their employees and the environment and inform the public about potential substance hazards.

While the intentions of REACH are clear and simple, in reality, this legislation is complicated and difficult to implement for many companies. The European Chemicals Agency (ECHA) has tried to help by publishing several detailed guidelines, but sometimes the explanations and examples caused more confusion. Substances that have to be registered by the 2018 deadline lie in the 1-100 tonne tonnages. Companies have to prepare registration dossiers for each substance, which contain substance information, such as toxicological and ecotoxicological tests, physicochemical properties, guidance for safe use and more. This is a big problem that manufacturers or importers have to face, as many of them have minimum information about their substances, and, because of REACH, they have to spend large sums of money on obtaining this information.

However, most pharmaceutical companies have the opportunity to register their substances as transported or isolated intermediates. According to REACH, on on-site isolated intermediate is defined as a substance, which is used for the manufacture of another substance, and takes place on the same site, whereas a transported isolated intermediate is moved between or supplied to other sites. Registering as an intermediate is a big advantage because the amount of information needed for the registration dossier and associated costs are significantly decreased. To be able to register these substances as intermediates, they have to be handled under strictly controlled conditions, which must be well-founded and documented. In the end, the simplified registration is not as simple as expected.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jana Osičková works as an officer in the department of Ecology and Emergency Prevention at Farmak – a traditional European generic API manufacturer in the Czech Republic. She graduated from Brno University of Technology, Czech Republic, with a master’s degree in food science and biotechnology. She is a specialist in REACH legislation and SCCs and is currently working on registering substances used and manufactured in Farmak. 
spacer
Jana Osičková
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Charles River Laboratories Announces Extended Relationship with The Michael J. Fox Foundation

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced an extension of its long-standing collaboration with The Michael J. Fox Foundation for Parkinson’s Research (MJFF), a leading organization working to support the diagnosis and treatment of Parkinson’s disease (PD). Since 2011, Charles River and MJFF have worked together to accelerate the discovery of therapies for PD. This latest extension includes grants from MJFF to support two projects:
More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

 
Industry Events

SAPHEX 2018

1-2 November 2018, Gallagher Convention Centre, Midrand, South Africa

The SAPHEX exhibition and conference is now established as the “go-to” networking and business event for anyone working in the South African pharmaceutical manufacturing industry.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement